MONDAY, Dec. 29 (HealthDay News) -- Botulinum toxin (BoNT) type A is a new, safe and effective non-invasive therapy for treatment of masseteric muscle hypertrophy to obtain lower facial contouring, according to research published in the November issue of the Journal of Craniofacial Surgery.
Gianpaolo Tartaro, M.D., of the 2nd University of Naples in Italy, and colleagues treated five masseteric muscle hypertrophy patients with BoNT type A in a clinical prospective study. The BoNT injection was administered percutaneously with varying dosages, generally in the thickest portion of the hypertrophied masseter muscle.
The investigators found that all five patients experienced satisfactory regression of the masseteric muscle hypertrophy after an average of 20 days following treatment. Only one patient required retreatment to attain satisfactory regression. The masseteric muscle was reduced in patients, and in only one case was a relapse noted after a six-month follow-up, the researchers report. This relapse was treated with a second injection, they note. After an average of five months, patients experienced muscular tone again. No patients experienced either local or systemic complications following BoNT injection, the report indicates.
"BoNT type A can safely be considered as a non-invasive drug treatment for patients with masseteric muscle hypertrophy," the authors write, adding that "it is very important to study the facial bones and desire of the patients."
Abstract
Full Text (subscription or payment may be required)
